SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

GTA VIs upcoming launch is driving attention, with traders debating whether anticipated blockbuster sales justify Take-Twos valuation. Bulls expect launch hype and future online monetization to support the stock, while bears point to priced-in expectations and risks around leaks, PC timing, and limited details on online features.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals proposed zero-coupon convertible-note offering has prompted a sharp selloff, with traders concerned about potential dilution, noteholder hedging and the timing of the financing. Others view it as low-cost capital for Barber Lake and the companys AI data-center expansion, leaving debate over near-term shareholder pressure versus growth funding.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

A jury found Arm breached its architectural license agreement with Qualcomm and intentionally disrupted Qualcomms business, drawing attention to the unresolved damages and possible royalty consequences. Traders view the verdict as a Qualcomm win, but debate its significance because damages are undisclosed and post-trial rulings remain pending.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Attention centers on the AI-agent CPU narrative: traders link Metas Muse adoption and its reported role as a lead partner for Arms AGI CPU to expectations of rising data-center CPU demand. Bulls view Arm as an AI-infrastructure beneficiary, while skeptics question its high valuation and whether expected demand will translate into revenue.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

A third-quarter earnings beat and raised full-year profit outlook, alongside improved medical-cost management, is driving discussion. Shares gave back early gains, splitting traders between seeing evidence of a turnaround and questioning why strong results failed to sustain the rally.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnsons quarterly results are driving attention: despite an adjusted earnings beat and higher full-year outlook, slower-than-expected MedTech growth and a sharp reported-earnings decline tied partly to one-time charges have accompanied a steep share drop. Traders are split between viewing the selloff as an overreaction and seeing the weakness and valuation as reasons for further caution.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention amid a steep selloff that traders say lacks a clear public catalyst. Debate centers on whether Auvelitys Alzheimers-agitation launch and prescription growth are weaker than expected or obscured by sampling and long-term-care data gaps; managements silence has heightened concerns about commercial execution and the path to profitability, while some investors argue the decline is broader biotech or market pressure.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

A fatal incident involving a rider on Six Flags Over Georgias Goliath coaster has driven safety and liability concerns, with traders discussing possible ride closures, reputational damage, and added pressure on the companys debt burden. Reactions range from fears of lasting business damage and bankruptcy to views that the selloff is an overreaction or buying opportunity.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is drawing attention for choppy trading and repeated failures to hold gains near resistance. Bulls cite analyst upgrades and enterprise-AI demand, while bears point to software-sector weakness and concerns that AI could disrupt SaaS companies.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgans quarterly results missed expectations, with weaker fixed-income trading and a securities loss weighing on earnings; stronger net interest income and lending provided an offset. Traders are divided over the stocks resilience despite the miss, with some viewing the core business and outlook as supportive while others expect the shortfall and Dimons economic-risk warnings to pressure shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX PSS just dropped a tweet most people will scroll past. Don&#39;t. 
 
&quot;First 20 subjects without cancer but with Lynch Syndrome.&quot; Without cancer. ANKTIVA is being tested to PREVENT cancer. Not treat. Prevent. Different market entirely. 
 
&quot;138 randomized to Anktiva plus our Adeno CANCER VACCINE versus placebo.&quot; Randomized. Placebo-controlled. Run by the National Cancer Institute (NCI) - Dr Jeff Schlom. Not ImmunityBio. Independent. 
 
&quot;Confirms the immune stimulating effect of Anktiva re ALC.&quot; ALC = Absolute Lymphocyte Count. Your immune army. NCI confirmed ANKTIVA grows it. 
 
&quot;As we age the baseline ALC is low but Anktiva changes that level.&quot; As we AGE. Not as we get cancer. ANKTIVA reverses age-related immune decline. NCI data. 
 
The JAMA paper: 1 in 5 Americans have low lymphocytes. 52 million people. Shorter lifespan. 
 
The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer. 
 
Connect the dots...

Hank

Lance

mr mulally

Paul Sprecher

GIMMEHAWKTUAH

Jkane

Day Trader

Reinhard

Johann

Larry

PureLand

Mark

Nesta

Jeremy Hill

Matt

A Yeo

afc2881

hoa nguyen

JLH1903

John Morin

Ulaughing

Agnes Garve

Alberto Lazzati

Rickerthestockpicker

harry

Dan Storey

Jack

J R T

$IBRX 
 
&quot;First 20 subjects without cancer but with Lynch Syndrome.&quot; Without cancer. ANKTIVA is being tested to PREVENT cancer. Not treat. Prevent. Different market entirely.&quot; 
 
hmmm. ummm, they entered the trial without cancer as well. this is not the day to be pulling this crap. wtf.

StockTwits Web

LMAO

StockTwits for iOS

Jack Daniel

ImmunityBio Inc

 PSS just dropped a tweet most people will scroll past. Don't. 
 
"First 20 subjects without cancer but with Lynch Syndrome." Without cancer. ANKTIVA is being tested to PREVENT cancer. Not treat. Prevent. Different market entirely. 
 
"138 randomized to Anktiva plus our Adeno CANCER VACCINE versus placebo." Randomized. Placebo-controlled. Run by the National Cancer Institute (NCI) - Dr Jeff Schlom. Not ImmunityBio. Independent. 
 
"Confirms the immune stimulating effect of Anktiva re ALC." ALC = Absolute Lymphocyte Count. Your immune army. NCI confirmed ANKTIVA grows it. 
 
"As we age the baseline ALC is low but Anktiva changes that level." As we AGE. Not as we get cancer. ANKTIVA reverses age-related immune decline. NCI data. 
 
The JAMA paper: 1 in 5 Americans have low lymphocytes. 52 million people. Shorter lifespan. 
 
The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer. 
 
Connect the dots...

ActionCuresFear

$IBRX Part Two: What the market doesn&#39;t see. 
 
The market prices IBRX as a bladder cancer drug ($113M revenue, 700% growth). This one PSS tweet confirms three things in no analyst model: 
 
1. Cancer PREVENTION platform. ANKTIVA + cancer vaccine preventing cancer in genetically predisposed patients. NCI running it. 138 enrolled. If this works, new category of medicine. 
 
2. Immune restoration. NCI data showing ANKTIVA raises ALC in aging populations. Not cancer patients - people whose immune systems decline with age. Every human being. 
 
3. Lymphopenia treatment. 52 million Americans. JAMA-validated. Significantly shorter lifespan. No approved treatment exists. 
 
Bladder cancer is what the market sees. Cancer prevention, immune restoration, and lymphopenia are what it doesn&#39;t. NCI is generating the data for all three. Independently. 
 
&quot;The cancer vaccine trials are underway!&quot; 
 
-------- 
More details on X: https://x.com/ActionFixesFear/status/2034909566362886416

Paul Cho

X (formerly Twitter)

 Part Two: What the market doesn't see. 
 
The market prices IBRX as a bladder cancer drug ($113M revenue, 700% growth). This one PSS tweet confirms three things in no analyst model: 
 
1. Cancer PREVENTION platform. ANKTIVA + cancer vaccine preventing cancer in genetically predisposed patients. NCI running it. 138 enrolled. If this works, new category of medicine. 
 
2. Immune restoration. NCI data showing ANKTIVA raises ALC in aging populations. Not cancer patients - people whose immune systems decline with age. Every human being. 
 
3. Lymphopenia treatment. 52 million Americans. JAMA-validated. Significantly shorter lifespan. No approved treatment exists. 
 
Bladder cancer is what the market sees. Cancer prevention, immune restoration, and lymphopenia are what it doesn't. NCI is generating the data for all three. Independently. 
 
"The cancer vaccine trials are underway!" 
 
-------- 
More details on X: 

@ActionCuresFear Just another BIG one in the pipeline. Staggering potential. GL$$$

 Just another BIG one in the pipeline. Staggering potential. GL$$$

If you want to spread the words, here is the original X post with more details: https://x.com/ActionFixesFear/status/2034909566362886416

Cynthia

If you want to spread the words, here is the original X post with more details: 

@ActionCuresFear a real life BIO- SHIELD!!!!  love it.. this is going to be yugeeee

 a real life BIO- SHIELD!!!!  love it.. this is going to be yugeeee